ArticleFrontiers in oncology2020

Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy.

Shan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.